Study reveals how reduced function of the rgs2 protein in the nucleus accumbens contributes to symptoms associated with depression. The findings may assist with the development of new therapeutics to help treat depression in individuals.
Researchers explain why the serotonin hypothesis for depression may not be as accurate as previously believed.
Genetic variants of the 5-HT2A serotonin receptor may explain why some respond to psychedelic therapies for the treatment of mental health disorders while others don't.
Researchers discuss how psychedelics can affect the brain and provide therapeutic benefits for those suffering from a range of psychiatric disorders.
Cannabidiol treatment helped reduce anxiety severity by, on average, 42.6% in young adults with treatment-resistant anxiety, a new study reports.
Researchers report several new direct acting antiviral, drugs commonly used to treat Hepatitis C, improve symptoms of PTSD.
Both those who experienced a natural near-death experience and those who had a near-death experience while taking psychedelics report less fear of death and a lasting, spiritual positive experience.
A new study reports two doses of the psychedelic compound psilocybin reduced heavy alcohol consumption by 83% when combined with therapy for those with alcohol use disorder.
Prescribing psychedelic therapies including MDMA and psilocybin in combination with counseling and psychotherapy improve symptoms for those with PTSD.
Study reveals a moderate link between antipsychotic use and an increased risk of developing breast cancer.
Loperamide, a common anti-diarrhea medication, could help treat core symptoms associated with autism spectrum disorder. The drug activates the μ-opioid receptor, helping to improve social behaviors.
Spironolactone, a medication commonly used to lower blood pressure and for treating heart-related problems, shows potential for the treatment of alcohol use disorder.
